+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 122 Pages
  • August 2024
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5997339
The Europe Tuberculosis Diagnostics Market would witness market growth of 4.4% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $181.1 million by 2031. The UK market is exhibiting a CAGR of 3.4% during (2024 - 2031). Additionally, The France market would experience a CAGR of 5.3% during (2024 - 2031).



The rise of multidrug-resistant tuberculosis (MDR-TB) represents a significant and growing challenge in the fight against TB. MDR-TB is a form of tuberculosis that is caused by bacteria that are resistant to at least two of the most potent first-line anti-TB drugs, which are rifampicin and isoniazid. This resistance makes MDR-TB much more difficult and costly to treat than drug-susceptible TB, and it has serious implications for public health, as the disease can spread to others, compounding the challenge of TB control. The emergence and spread of MDR-TB have highlighted the critical need for advanced diagnostic tools that can quickly and accurately identify resistant strains, enabling appropriate treatment to be initiated promptly.

The market is not without its challenges. Despite the progress made in developing advanced diagnostic tools, significant barriers remain in terms of accessibility and affordability, particularly in low-income countries where the burden of TB is greatest. Many advanced diagnostic tools are expensive and require infrastructure and expertise, which are often lacking in these settings. This has led to a persistent reliance on older, less effective diagnostic methods, such as smear microscopy, which, while affordable and easy to use, have significant limitations regarding sensitivity and specificity.

TB prevention and awareness programs in France are primarily managed by Santé publique France, the national public health agency. The agency runs national campaigns to raise awareness about TB, particularly in high-incidence areas like Île-de-France. These campaigns often include informational materials distributed in multiple languages to reach immigrant communities and other at-risk groups. The Ministry of Health (Ministero della Salute) coordinates Italy's TB prevention and awareness efforts, focusing on migrant and refugee populations. The country has mandated TB screening for newly arrived asylum seekers as part of a more comprehensive strategy to prevent the transmission of TB within migrant communities. Public health campaigns in Italy are designed to raise awareness about TB symptoms and encourage individuals to seek medical care early. Therefore, as countries across the region continue to implement and refine their TB control strategies, the demand for innovative diagnostics is expected to rise.

Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

  • Abbott Laboratories
  • Qiagen N.V
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • F.Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Bruker Corporation

Market Report Segmentation

By End Use
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others
By Type
  • Detection of Latent Infection (Skin Test & IGRA)
  • Phage Assay
  • Detection of Drug Resistance (DST)
  • Nucleic Acid Testing
  • Radiographic Method
  • Cytokine Detection Assay
  • Diagnostic Laboratory Methods
  • Other Methods
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Tuberculosis Diagnostics Market, by End Use
1.4.2 Europe Tuberculosis Diagnostics Market, by Type
1.4.3 Europe Tuberculosis Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Europe Tuberculosis Diagnostics Market by End Use
4.1 Europe Diagnostic Laboratories Market by Country
4.2 Europe Hospitals & Clinics Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Tuberculosis Diagnostics Market by Type
5.1 Europe Detection of Latent Infection (Skin Test & IGRA) Market by Country
5.2 Europe Phage Assay Market by Country
5.3 Europe Detection of Drug Resistance (DST) Market by Country
5.4 Europe Nucleic Acid Testing Market by Country
5.5 Europe Radiographic Method Market by Country
5.6 Europe Cytokine Detection Assay Market by Country
5.7 Europe Diagnostic Laboratory Methods Market by Country
5.8 Europe Other Methods Market by Country
Chapter 6. Europe Tuberculosis Diagnostics Market by Country
6.1 Germany Tuberculosis Diagnostics Market
6.1.1 Germany Tuberculosis Diagnostics Market by End Use
6.1.2 Germany Tuberculosis Diagnostics Market by Type
6.2 UK Tuberculosis Diagnostics Market
6.2.1 UK Tuberculosis Diagnostics Market by End Use
6.2.2 UK Tuberculosis Diagnostics Market by Type
6.3 France Tuberculosis Diagnostics Market
6.3.1 France Tuberculosis Diagnostics Market by End Use
6.3.2 France Tuberculosis Diagnostics Market by Type
6.4 Russia Tuberculosis Diagnostics Market
6.4.1 Russia Tuberculosis Diagnostics Market by End Use
6.4.2 Russia Tuberculosis Diagnostics Market by Type
6.5 Spain Tuberculosis Diagnostics Market
6.5.1 Spain Tuberculosis Diagnostics Market by End Use
6.5.2 Spain Tuberculosis Diagnostics Market by Type
6.6 Italy Tuberculosis Diagnostics Market
6.6.1 Italy Tuberculosis Diagnostics Market by End Use
6.6.2 Italy Tuberculosis Diagnostics Market by Type
6.7 Rest of Europe Tuberculosis Diagnostics Market
6.7.1 Rest of Europe Tuberculosis Diagnostics Market by End Use
6.7.2 Rest of Europe Tuberculosis Diagnostics Market by Type
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Qiagen N.V
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.2.6 SWOT Analysis
7.3 Thermo Fisher Scientific, Inc
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.3.6 SWOT Analysis
7.4 Becton, Dickinson, and Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.6 SWOT Analysis
7.5 F. Hoffmann-La Roche Ltd
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and Mergers:
7.5.6 SWOT Analysis
7.6 Hologic, Inc
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 DiaSorin S.p.A
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Bruker Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Revvity, Inc
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis

Companies Mentioned

  • Abbott Laboratories
  • Qiagen N.V
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Bruker Corporation
  • Revvity, Inc.

Methodology

Loading
LOADING...